Atreca Appoints Acclaimed Immunologist Lewis L. Lanier, Ph.D., As A Technical Advisor

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Atreca, Inc., a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, announced today the appointment of Lewis L. Lanier, Ph.D., as a technical Advisor. Dr. Lanier is a world-renowned immunologist who over the past 35 years has identified many of the key receptors, ligands, and signaling pathways of natural killer (NK) cells and has defined their roles in innate and adaptive immune responses to pathogens and cancer.

“His deep expertise and critical insights will be an asset to Atreca as we rapidly advance our lead programs in immuno-oncology.”

“We are very pleased that Lewis Lanier is becoming an Atreca technical Advisor,” said Lawrence Steinman, M.D., Co-Founder and Director of Atreca, and the George A. Zimmermann Professor of Neurology and Neurological Sciences and Pediatrics in the Stanford University School of Medicine. “His deep expertise and critical insights will be an asset to Atreca as we rapidly advance our lead programs in immuno-oncology.”

“Atreca is advancing a pipeline of first-in-class programs, enabled by our highly productive and high-fidelity Immune Response Capture™ (IRC™) technology, and supported by industry-leading advisors, investors, and collaborators,” said Tito A. Serafini, Ph.D., Atreca’s President, Chief Executive Officer, and Co-Founder. “Lewis offers a valuable voice and perspective as we accelerate our programs toward the clinic.”

Lewis L. Lanier is an American Cancer Society Professor and the J. Michael Bishop MD Distinguished Professor and Chairman of the Department of Microbiology and Immunology at the University of California, San Francisco (UCSF), and a member of the National Academy of Sciences. Dr. Lanier is also Leader of the Cancer, Immunity, and Microenvironment Program of the UCSF Helen Diller Comprehensive Cancer Center. He has been recently named to lead the UCSF center of the Parker Institute for Cancer Immunotherapy. Previously, Dr. Lanier was Director of Immunobiology at DNAX Research Institute of Molecular and Cellular Biology in Palo Alto, California. He began his career at Becton Dickinson Monoclonal Center, Inc., advancing to Associate Research Director at Becton Dickinson Immunocytometry Systems. Dr. Lanier has received many honors and awards in recognition of his scientific contributions, including the William B. Coley Award for Distinguished Research in Basic Tumor Immunology from the Cancer Research Institute (2002), and is Past President of the American Association of Immunologists. Dr. Lanier received B.S. degree in microbiology from Virginia Polytechnic Institute & State University, Blacksburg, his Ph.D. degree in immunology from the University of North Carolina Chapel Hill, and a second Ph.D. in immunology from the University of New Mexico Medical School, Albuquerque.

Dr. Lanier commented, “Atreca is unique in leveraging a broadly enabling technology that characterizes human immune responses to cancer in order to develop new treatments and treatment paradigms. I look forward to working with the team as they advance their programs and exploit the full potential of this platform.”

About Atreca, Inc.

Atreca is a privately held biotechnology company developing novel therapeutics drawn from human immune responses, including effective anti-cancer immune responses. We are able to measure and analyze the structure of clinically relevant immune responses to identify the antibodies, T cell receptors, and targets that are key to successful treatment outcomes. Atreca’s proprietary Immune Repertoire Capture™ technology profiles a patient’s immune response at the single-cell level at very high throughput without bias or error, enabling the identification and generation of functional human antibodies and TCRs without prior knowledge of antigen. The Company is advancing a pipeline of candidates with the objective of enhancing engagement of the human immune response in cancer treatment and other indications, thus optimizing therapeutic outcomes. For more information on Atreca, please visit


Atreca, Inc.
Susan Berland
EVP and Chief Financial Officer
Justin Jackson, 212-213-0006, ext. 327

Back to news